Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome
Key Secondary Objective
• To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome
Quick Facts
Study Start:2025-06-15
Study Completion:2026-03-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
Biomed Testing Facility # BIO-01-85012
Phoenix, Arizona, 85012
United States
Biomed Testing Facility # BIO-05-92093
La Jolla, California, 92093
United States
Biomed Testing Facility # BIO-04-90095
Los Angeles, California, 90045
United States
Biomed Testing Facility # BIO-03-95817
Sacramento, California, 95817
United States
Biomed Testing Facility # BIO-02-94104
San Francisco, California, 94104
United States
Biomed Testing Facility #BIO-06-80042
Aurora, Colorado, 80042
United States
Biomed Testing Facility #BIO-07-33606
Tampa, Florida, 33606
United States
Biomed Testing Facility #BIO-08-60612
Chicago, Illinois, 60612
United States
Maryland Locations Biomed Testing Facility #BIO-9-21205
Baltimore, Maryland, 21205
United States
Biomed Testing Facility #BIO-10-02115
Boston, Massachusetts, 02115
United States
Minnesota Locations Biomed Testing Facility #BIO-11-55101
Saint Paul, Minnesota, 55101
United States
Missouri Locations Biomed Testing Facility #BIO-12-63110
Saint Louis, Missouri, 63110
United States
Biomed Testing Facility #BIO-13-10467
Bronx, New York, 10467
United States
Biomed Testing Facility #BIO-14-27599
Chapel Hill, North Carolina, 27599
United States
Biomed Testing Facility #BIO-15-45229
Cincinnati, Ohio, 45229
United States
Biomed Testing Facility #BIO-16-44195
Cleveland, Ohio, 44195
United States
Biomed Testing Facility #BIO-17-19104
Philadelphia, Pennsylvania, 19104
United States
Biomed Testing Facility #BIO-18-37232
Nashville, Tennessee, 37232
United States
Biomed Testing Facility #BIO-19-77030
Houston, Texas, 77030
United States
Biomed Testing Facility #BIO-20-98105
Seattle, Washington, 98105
United States
Collaborators and Investigators
Sponsor: Biomed Industries, Inc.
- Lloyd L Tran, PhD, STUDY_DIRECTOR, Biomed Industries, Inc.
- David Nguyen, PhD, STUDY_DIRECTOR, Biomed Industries, Inc.
- Zung V Tran, PhD, STUDY_DIRECTOR, Biomed Industries, Inc.
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2025-06-15
Study Completion Date2026-03-15
Study Record Updates
Study Start Date2025-06-15
Study Completion Date2026-03-15
Terms related to this study
Keywords Provided by Researchers
- Rett syndrome,
- Genetic Diseases, X-Linked
Additional Relevant MeSH Terms